Scarica l'app Stockscreener
44.06
0.92%
0.40
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighHere's What Happened - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC's 3rd Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. $XENE is Affinity Asset Advisors LLC’s 3rd Largest Position - Defense World
Evaluating Xenon Pharmaceuticals (XENE)’s Valuation After Its Recent Share Price Rebound - Sahm
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD By Investing.com - Investing.com India
XENE Unveils Promising Data on Epilepsy Treatment Advances - GuruFocus
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD - Investing.com
Xenon Pharmaceuticals Unveils Promising Long-Term Epilepsy Treatment Data - TipRanks
Xenon Pharmaceuticals Reports Significant Long-Term Efficacy of Azetukalner in Epilepsy at AES 2025 - Quiver Quantitative
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 - The Manila Times
Saturn V Capital Management LP Boosts Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How Xenon Pharmaceuticals Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares By Investing.com - Investing.com Canada
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares - Investing.com
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - sharewise.com
Xenon Pharmaceuticals to Host Webinar on Epilepsy Data and Commercialization Plans - TipRanks
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025 - GlobeNewswire
JPMorgan Chase & Co. Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Loomis Sayles & Co. L P Sells 15,846 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
American Century Companies Inc. Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Expands 2025 Equity Incentive Plan - TipRanks
(XENE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Ameritas Investment Partners Inc. Acquires Shares of 7,758 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Franklin Resources Inc. Purchases 175,346 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Geode Capital Management LLC Purchases 900,746 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention - Sahm
Xenon Reports Second Quarter 2025 Financial Results & Business Update - ADVFN
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD - Investing.com
Intech Investment Management LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):